ClinicalTrials.gg
TerminatedNCT00832624Updated May 23, 2017Results posted

The Effect of Sitagliptin in Type 2 Diabetes Mellitus With Inadequate Glycemic Control (MK0431-118)

A Phase 4 interventional study of sitagliptin in Diabetes Mellitus Non-insulin-dependent, sponsored by Merck Sharp & Dohme LLC. Terminated. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-05-23.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 4, Interventional, and Treatment

Why this study was terminated
Business Reasons

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
10
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.

Enrollment
186th of 197
10 · median 102
Started
2008
with 22 others
Phase 4
68 of 198
3 open now
Registered
61st of 198
by date
Lead sponsor
70 of 198
Merck Sharp & Dohme LLC

Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 186th largest by enrollment of the 197 interventional ones that give a count, is one of 23 that started in 2008, is one of 68 in phase 4, and was the 61st registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About sitagliptin

sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

to assess the effect of treatment with Sitagliptin (MK0431) on HbA1c (Hemoglobin A1c) and the safety and tolerability of Sitagliptin.

03

Conditions studied

  • Diabetes Mellitus Non-insulin-dependent
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Patients Who Are 18 Years Of Age With Type 2 Diabetes Mellitus Who Are Either:

    • Not On Antihyperglycemic (AHa) Medication (Off For At Least 2 Months)
    • Or On A Single AHa
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    1

    sitagliptin

    Drug: sitagliptin

Interventions

  • Sitagliptin, 100 mg, 1 Tablet, once a day, for 18 weeks

    Also known as: Januvia, MK0431

06

What researchers measure

Primary outcomes

  1. Change From Baseline in HbA1c (Hemoglobin A1c) at Week 18

    Glycosylated hemoglobin (HbA1c) was to be measured as the percentage of hemoglobin that has glucose bound to it; however, the study was terminated early therefore no laboratory tests were performed, and no outcome data was collected.

    Time frame: Baseline and Week 18

07

Results

Posted Oct 11, 2010
Limitations and caveats
The planned 18-week study was terminated early due to reconsideration of the study design. None of the 10 patients progressed beyond the second study visit, no laboratory tests were performed, and adverse experience data were not collected.

Participant flow

Recruitment process occurred in the Hospital Regional de Taguatinga between November, 26 2008 and May, 27 2009. First Patient in: 26-Nov-2008; Last patient in: 27- May- 2009

Participant flow — Overall Study
MilestoneSitagliptin 100 mg
Started10
Completed0
Not completed10
Withdrew: Study terminated10

Outcome measures

PrimaryChange From Baseline in HbA1c (Hemoglobin A1c) at Week 18

Glycosylated hemoglobin (HbA1c) was to be measured as the percentage of hemoglobin that has glucose bound to it; however, the study was terminated early therefore no laboratory tests were performed, and no outcome data was collected.

Time frame:
Baseline and Week 18

No measurements were reported for this outcome.

Adverse events

Collected over The planned 18-week study was terminated early due to reconsideration of the study design.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sitagliptin 100 mg———

Baseline characteristics

Age, Continuous
Age, Continuous(years)Sitagliptin 100 mg
Mean51.7 ± 14.0
Sex: Female, Male
Sex: Female, Male(Participants)Sitagliptin 100 mg
Female9
Male1
Region of Enrollment
Region of Enrollment(participants)Sitagliptin 100 mg
Brazil10
Weight
Weight(Kilograms)Sitagliptin 100 mg
Mean71.59 ± 11.55
08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2008 to primary completion in Sep 2009, 9 months.

Results were first posted in Oct 2010, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2009
First posted
Jan 30, 2009
StartActual
Nov 26, 2008
Primary completionActual
Sep 2, 2009
CompletionActual
Sep 2, 2009
Results first posted
Oct 11, 2010
Last update
May 23, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 23, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00832624
Responsible party
Sponsor
First posted
Jan 30, 2009
Start date
Nov 26, 2008
Primary completion
Sep 2, 2009
Completion
Sep 2, 2009
Results posted
Oct 11, 2010
Last update
May 23, 2017

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sitagliptin

Start the discussion